Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate (ANES)

Bayer

Status: Terminated

Conditions: Prostate Cancer

Treatments: Drug: Cyproterone Acetate (Androcur, BAY94-8367)

Study type: Observational

Funder types: Industry

Identifiers

NCT00919022

AC0910CZ (Other Identifier)

14556

Details and patient eligibility

About

Cyproterone acetate (CPA) is a steroidal antiandrogen which has affinity with progesterone and with glucocorticoid receptors. Cyproterone acetate is long-term proven effective treatment of inoperable carcinoma of the prostate.

Sexual functions remain very important in men with prostate cancer. However sexual functions are deteriorating fast with course of the disease. The influence of CPA on sexual functions remains controversial. IIEF-5 erectile dysfunction questionnaire is currently widely used validated simple scoring system for diagnosing of erectile dysfunction and belongs to most used systems in Czech Republic. At present there are no data on CPA influence on IIEF-5 scored erectile dysfunction within the use of its indication in prostate cancer.

Enrollment: 194 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males > 18 years previously untreated with Androcur.
• No contraindication to Androcur.

Exclusion criteria

• Liver diseases, malignant liver tumours and wasting diseases (except for carcinoma of the prostate). A history of or existing thrombosis or embolism. Severe chronic depression. Hypersensitivity to cyproterone. Cyproterone acetate in previous therapy.

Trial design

194 participants in 1 patient group

Group 1

Treatment:

Drug: Cyproterone Acetate (Androcur, BAY94-8367)